The present invention relates to the use of a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated biological activity compared to the respective wild type IL-8 for preparing a medicament for the prevention and/or treatment of ischemia reperfusion injury and/or transplant rejection in patients.